title: Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects.
abstract: The in vivo turnover of autologous lipoprotein(a) (Lp(a)) was studied in four heterozygous familial hypercholesterolaemic (FH) subjects and four subjects who were hyperlipidaemic but not FH. Each of the FH subjects exhibited a much lower fractional catabolic rate (FCR) for LDL than each of the non-FH subjects. Lp(a) was purified by sequential density gradient centrifugations and was radio-iodinated. The labelled Lp(a) ran as a single band on electrophoresis in gradient polyacrylamide gels. Less than 5% of the label was in lipid, with about 40% of the remainder on apolipoprotein B (apo B) and 60% on apo(a). Labelled and unlabelled Lp(a) competed equally poorly with LDL for binding to LDL receptors on cultured fibroblasts. The FCR of Lp(a), calculated from the decay of the specific radioactivity of the Lp(a) isolated from the daily blood samples, was the same in FH subjects as in non-FH subjects. There was no consistent relationship between Lp(a) FCR and the plasma Lp(a) concentration or between FCR and the Lp(a) phenotype, at least within this sample of subjects. There was a strong association between Lp(a) concentration and production rate, with values for non-FH and FH subjects falling on the same line. The rate of decline of radioactivity in whole plasma was consistently slower than the fall in specific radioactivity of the isolated Lp(a). This difference was more marked in FH subjects than in non-FH subjects and resulted from the accumulation of radioactivity derived from the injected Lp(a) at a lower density than Lp(a), in the fractions containing LDL. The amount of radioactivity in this fraction increased for the first few days after injection and then fell, the fall being more rapid in non-FH than in FH subjects. These results provide no evidence for the involvement of LDL receptors in the catabolism of Lp(a) itself but suggest that they could be responsible for some of the clearance of the lipid and apo B components after removal of apo(a) in the circulation.
authors.affiliation: MRC Lipoprotein Team, Hammersmith Hospital, London, U.K.
authors.forename: B L
authors.initials: BL
authors.lastname: Knight
authors.forename: Y F
authors.initials: YF
authors.lastname: Perombelon
authors.forename: A K
authors.initials: AK
authors.lastname: Soutar
authors.forename: D P
authors.initials: DP
authors.lastname: Wade
authors.forename: M
authors.initials: M
authors.lastname: Seed
mesh_terms: D000328:Adult; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000378:metabolism; D006938:Hyperlipoproteinemia Type II / Q000097:blood* / Q000378:metabolism; D017270:Lipoprotein(a); D008074:Lipoproteins / Q000097:blood / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011973:Receptors, LDL / Q000378:metabolism
chemical_list: D017270:Lipoprotein(a); D008074:Lipoproteins; D008077:Lipoproteins, LDL; D011973:Receptors, LDL